Lasix is the brand name for furosemide, a loop diuretic prescribed for fluid retention, high blood pressure, heart failure and certain kidney conditions. It is not a controlled substance, and it is not one of the drug classes that a standard workplace or clinical urine panel is built to detect. A person taking furosemide as prescribed should not expect it to trigger a positive result on a 5 panel, 10 panel, oral fluid, or lab confirmation test for amphetamines, opioids, cocaine metabolite, THC, PCP, benzodiazepines, or barbiturates.
The question that actually matters for employers and donors is different from "does it show up." Because furosemide increases urine output, it can change the concentration of a urine specimen enough that a laboratory flags the sample as dilute during specimen validity testing, a separate step from the drug screen itself. That is the real compliance issue, and it is the one this article walks through.
Screening immunoassay versus confirmation testing
A rapid cup or dip card uses an immunoassay: antibodies bind to a target drug class and a threshold concentration triggers a line change. Immunoassays are built around specific drug families, and cross reactivity happens when an unrelated compound has a similar enough structure to trigger the same antibody. A nonnegative screen on any panel is never reported as final; it is sent to a laboratory for gas chromatography mass spectrometry (GC/MS) or liquid chromatography mass spectrometry (LC/MS) confirmation, which identifies the exact molecule rather than a class reaction.
Furosemide's structure (a sulfonamide loop diuretic) does not match the antibody targets used in the opioid, amphetamine, cannabinoid, cocaine, PCP, benzodiazepine, or barbiturate immunoassay classes found in standard workplace panels. There is no published cross reactivity evidence tying furosemide to a false positive on any of those panels. The FDA labeling for Lasix on DailyMed lists furosemide's indications, warnings and interactions, and does not identify drug screen cross reactivity as a known effect. The National Library of Medicine's MedlinePlus furosemide monograph likewise describes furosemide only as a diuretic used for fluid retention and blood pressure, with no connection to the drug classes a workplace panel screens for.
Why a diuretic can still cause a problem, dilute specimens
Workplace and DOT regulated drug testing does not stop at the drug panel. Every laboratory specimen also goes through specimen validity testing to check whether the sample is consistent with normal human urine. Under 49 CFR Part 40, the federal workplace drug testing procedure rule, a laboratory must treat a primary urine specimen as dilute when the creatinine concentration is at least 2 mg/dL but under 20 mg/dL, and the specific gravity is above 1.0010 but under 1.0030 on the same aliquot. Because furosemide increases urine volume, a donor taking it, or any diuretic, is more likely to produce a specimen that happens to land in that dilute range, through ordinary physiology rather than any attempt to interfere with the test.
A dilute finding is not an adulteration finding and it is not treated as a refusal. Under the same rule, if the reported drug result is positive, the employer treats it as a verified positive regardless of dilution. If the result is negative and dilute, the outcome depends on the creatinine level: a creatinine between 2 and 5 mg/dL requires an immediate recollection under direct observation, while a creatinine above 5 mg/dL gives the employer discretion to request one additional test, applied consistently across similarly situated employees rather than case by case.
For a closer look at how the creatinine and specific gravity cutoffs work and what a lab report actually shows, see our related post on creatinine levels on a drug test, and for the full list of validity tests a certified lab runs on every specimen, see specimen validity testing explained.
Masking agents and sports or athletic testing
Outside the employment context, many competitive sports drug testing programs place diuretics, including furosemide, in a separate prohibited category commonly described as masking agents. The concern in that setting is not that the diuretic itself is a performance enhancer, but that a large increase in urine volume can lower the concentration of other prohibited substances below a program's reporting threshold. Workplace programs address the same physiological effect through the specimen validity rules described above rather than through a banned substance list, which is why a prescribed diuretic is a documentation issue for an employee, not grounds for discipline on its own.
The medical review officer process
Every nonnegative or problem result under a regulated testing program goes through a medical review officer (MRO), a licensed physician trained to interpret laboratory results in light of legitimate medical explanations. A donor who is taking Lasix or any other prescribed diuretic should keep current prescription documentation available and be prepared to discuss it with the MRO if asked, rather than disclosing it informally to a collector or supervisor. The MRO, not the collection site and not the employer, is the party authorized to evaluate whether a medical condition or medication explains a validity finding. This article does not offer medical or dosing advice; any question about continuing, adjusting, or timing a prescribed medication belongs with the prescribing clinician.
The same documentation habit applies outside DOT regulated testing. Non-DOT federal workplace programs follow HHS Mandatory Guidelines for Federal Workplace Drug Testing Programs, published through notice in the Federal Register, which use the same specimen validity concept that 49 CFR Part 40 applies to DOT regulated employees. A private employer running a voluntary program generally sets its own policy for how a dilute result or a disclosed prescription is handled, so the donor's best practice is the same regardless of which program applies, keep the prescription on file and route any question to the MRO rather than guessing at the outcome in advance.
Diuretics and specimen validity, quick reference
| Diuretic or related drug | Typical prescribed use | Target of standard drug panels | Specimen validity note |
|---|---|---|---|
| Furosemide (Lasix) | Edema, heart failure, hypertension | No, not a panel analyte | Can lower creatinine and specific gravity, raising dilute specimen risk |
| Hydrochlorothiazide | Hypertension | No, not a panel analyte | Same dilute specimen mechanism as other diuretics |
| Spironolactone | Heart failure, hypertension, fluid retention | No, not a panel analyte | Potassium sparing diuretic, same dilute specimen consideration |
| Chlorthalidone | Hypertension | No, not a panel analyte | Long acting thiazide like diuretic, same dilute specimen consideration |
| Acetazolamide | Glaucoma, altitude sickness, fluid retention | No, not a panel analyte | Weaker diuretic effect, still capable of contributing to a dilute result |
| Deliberate water loading | Not a medical use | Not applicable | Same creatinine and specific gravity cutoffs apply regardless of intent |
What employers and donors should take away
Furosemide is not part of any standard immunoassay panel and there is no credible cross reactivity evidence connecting it to a false positive on the drug classes those panels screen for. Its real, documented interaction with testing is physiological: as a diuretic, it increases urine volume, and that can push a specimen's creatinine and specific gravity into the range federal rules define as dilute. A dilute result has defined, limited consequences under 49 CFR Part 40, it is not an accusation of cheating, and a prescription on file with the MRO is the correct way to document it. Programs that follow the Substance Abuse and Mental Health Services Administration's drug free workplace framework build their collection, laboratory, and MRO procedures around the same specimen validity concept, whether the program is DOT regulated or voluntary.
Employers building or auditing a collection and testing program can find compliant specimen cups, oral fluid collectors and lab confirmation services through American Screening Corporation's drug test cup collection.
Frequently asked questions
Does Lasix show up on a standard 5 panel or 10 panel drug test?
No. Furosemide is not one of the drug classes those immunoassay panels are built to detect, and there is no published cross reactivity evidence showing it triggers a positive result on those panels.
Is furosemide a controlled substance?
No. Furosemide is a prescription diuretic, not a scheduled controlled substance, and it is not included in federal workplace drug testing panels.
Can Lasix cause a false positive on a drug test?
There is no credible published evidence of furosemide causing a false positive on standard immunoassay panels. Any nonnegative screening result is always confirmed by GC/MS or LC/MS before it is reported, which rules out a cross reactivity error.
Why would a lab report a dilute specimen after someone takes a diuretic?
Diuretics increase urine output, which can lower creatinine and specific gravity enough to meet the federal definition of a dilute specimen. This is a specimen validity finding, separate from the drug panel result.
What happens if a workplace drug test comes back dilute?
Under 49 CFR Part 40, a dilute positive is still treated as a verified positive. A dilute negative may require an immediate observed recollection if creatinine is between 2 and 5 mg/dL, or may allow the employer discretion to request one additional test if creatinine is above 5 mg/dL, applied consistently across employees.
Does a prescription for Lasix need to be reported to the MRO?
A donor should keep current prescription documentation available and be ready to provide it to the medical review officer if a result raises a question. The MRO, not the employer or collection site, evaluates medical explanations for a result.
This article is general information about drug testing science and procedure, not legal or medical advice. Employers should consult qualified counsel and a medical review officer for guidance specific to their program, and donors with questions about a prescribed medication should consult the prescribing clinician.
